Reporting and Follow-up. Results from the FFMP shall be compiled and reported to the Compliance Officer for review and remediation as appropriate.
Reporting and Follow-up. Results from the FFMP shall be compiled and reported to the Compliance Officer for review and remediation as appropriate. Potential violations related to improper promotion of a Government Reimbursed Product or potential violations of Federal health care program or FDA requirements shall be reported to the Compliance Officer for appropriate follow-up activity. In the event that a compliance issue, including but not limited to any potential improper promotion or noncompliance with Indivior’s Policies and Procedures or legal or compliance requirements, is identified during any portion of the FFMP, Indivior shall investigate the incident consistent with established Policies and Procedures for the handling of investigations. As part of the investigative procedures, findings shall be made and all necessary and appropriate responsive action (including disciplinary action) and corrective action shall be taken, including the disclosure of Reportable Events pursuant to Section III.J above, as applicable. Any compliance issues identified during the FFMP and any corrective action shall be recorded in the files of the Compliance Officer.
Reporting and Follow-up. Personnel conducting the Speaker Program Audits, Observations, and Records Reviews shall have access to all relevant records and information necessary to assess potential or actual compliance violations. Results from the FFMP audits, including the identification of potential violations of policies and/or legal requirements, shall be compiled and reported to the Compliance Officer (or compliance personnel designee) for review and follow-up as appropriate. In the event that a potential violation of GSK’s Policies and Procedures or of legal or compliance requirements, including but not limited to potential off-label promotion, is identified during any aspect of the FFMP, GSK shall investigate the incident consistent with established policies and procedures for the handling of investigations and shall take all necessary and appropriate responsive action (including disciplinary action) and corrective action, including the disclosure of Reportable Events pursuant to Section III.J above, if applicable. Any compliance issues identified during a Speaker Program Audit, GlaxoSmithKline LLC Corporate Integrity Agreement Observation and/or Records Review and any corrective action shall be recorded in the files of the Compliance Officer (or compliance personnel designee). GSK shall include a summary of the FFMP and the results of the FFMP as part of each Annual Report. As part of each Annual Report, GSK also shall provide the OIG with copies of the Observation report for any instances in which it was determined that improper promotion occurred and a description of the action(s) that GSK took as a result of such determinations. GSK shall make the Observation reports for all other Observations available to the OIG upon request.
Reporting and Follow-up. Personnel conducting the Speaker Program Audits, Observations, and Records Reviews shall have access to all relevant records and information necessary to assess Forest’s interactions with HCPs and HCIs and to identify potential or actual compliance violations. Results from FFMP audits, including the identification of potential violations of policies and/or legal requirements, shall be compiled and reported to the Compliance Officer for review and follow up as appropriate. In the event that a potential violation of Forest’s Policies and Procedures and/or of legal or compliance requirements, including but not limited to potential off-label promotion, is identified during any aspect of the FFMP, Forest shall investigate the incident consistent with established Policies and Procedures for the handling of investigations and shall take all necessary and appropriate responsive action (including disciplinary action) and corrective action, including the disclosure of Reportable Events pursuant to Section III.H above, if applicable. Any compliance issues identified during a Speaker Program Audit, Observation and/or Records Review and any corrective action shall be recorded in the files of the Compliance Department. Forest shall include a summary of the FFMP and the results of the FFMP as part of each Annual Report. As part of each Annual Report, Forest also shall provide the OIG with copies of the Observation Report for any instances in which it was determined that improper promotion occurred and a description of the action(s) that Forest took as a result of such determinations. Forest shall make the Observation Reports for all other Observations available to the OIG upon request.
Reporting and Follow-up. Personnel conducting the Speaker Program Audits, Observations, and Records Reviews shall have access to all relevant records and information necessary to assess potential or actual compliance violations. Results from the FFMP audits, including the identification of potential violations of policies and/or legal requirements, shall be compiled and reported to the Compliance Officer (or compliance personnel designee) for review and follow-up as appropriate. In the event that a potential violation of Par’s Policies and Procedures or of legal or compliance requirements, including but not limited to potential off-label promotion, is identified during any aspect of the FFMP, Par shall investigate the incident consistent with established policies and procedures for the handling of investigations and shall take all necessary and appropriate responsive action (including disciplinary action) and corrective action, including the disclosure of Reportable Events pursuant to Section III.J above, if applicable. Any compliance issues identified during a Speaker Program Audit, Observation and/or Records Review and any corrective action shall be recorded in the files of the Compliance Officer (or compliance personnel designee). Par shall include a summary of the FFMP and the results of the FFMP as part of each Annual Report. As part of each Annual Report, Par also shall provide the OIG with copies of the Observation report for any instances in which it was determined that improper promotion occurred and a description of the action(s) that Par took as a result of such determinations. Par shall make the Observation reports for all other Observations available to the OIG upon request. Par Corporate Integrity Agreement
Reporting and Follow-up. Personnel conducting the Speaker Program Audits, Observations, and Records Reviews shall have access to all relevant records and information necessary to assess potential or actual compliance violations. Results from the FFMP audits, including the identification of potential violations of policies and/or legal requirements, shall be compiled and reported to the U.S. Compliance Department for review and follow-up as appropriate. In the event that a potential violation of AstraZeneca’s Policies and Procedures or of legal or compliance requirements, including but not limited to potential off-label promotion, is identified during any aspect of the FFMP, AstraZeneca shall investigate the incident consistent with established Policies and Procedures for the handling of investigations and shall take all necessary and appropriate responsive action (including disciplinary action) and corrective action, including the disclosure of Reportable Events pursuant to Section III.H above, if applicable. Any compliance issues identified during a Speaker Program Audit, Observation and/or Records Review and any corrective action shall be recorded in the files of the U.S.
Reporting and Follow-up. Monitoring personnel’s assessments and documentation of the results from monitoring Transactional Activities and Field-Based Activities shall be compiled, retained, and reported to the Compliance organization and other appropriate organizations within the J&J Pharmaceutical Affiliates for review and follow-up as appropriate. In the event that a finding of a monitoring assessment indicates that an activity has raised one or more potential compliance concerns or issues for follow-up, a member of the Compliance organization shall review and assess the significance of the finding. If the finding is determined by the Compliance organization to present a potential significant compliance issue, the finding shall be reported to the NALT Compliance Officer. The finding shall also be referred to the appropriate department within the Compliance organization or the J&J Pharmaceutical Affiliates, including but not limited to, the Compliance organization’s Internal Investigations program to respond to the finding consistent with established policies and procedures for the triage and handling of potential noncompliance and to ensure all necessary and appropriate responsive (including disciplinary) and corrective actions are taken, including the disclosure of Reportable Events pursuant to Section III.J, if applicable. Any compliance issues identified during monitoring assessments, and any corrective action taken as a result of the findings identified in the course of the monitoring of Transactional Activities or Field-Based Activities, shall be recorded in the files of the Compliance organization. The J&J Pharmaceutical Affiliates shall include in each Annual Report a summary of the Healthcare Compliance Monitoring program and the results of the monitoring activities conducted for Transactional Activities and Field- Based Activities. The J&J Pharmaceutical Affiliates shall make documents relating to its monitoring of Transactional Activities and Field-Based Activities available to the OIG upon request.
Reporting and Follow-up. The goals and indicators that are linked to the Municipality’s environment-related steering documents are followed up annually in connection with the director’s report and the annual report. In order to promote good transparency and enable citizens and other stakeholders to follow Järfälla’s environmental development, all statistics are presented at xxxxx://xxxxxxxx.xxxxxxxxxxxxxxx.xx/. During 2021, Järfälla participated in the One Planet City Challenge (OPCC), and then reported statistics and climate data to an international data platform led by CDP and ICLEI. By reporting climate data, the Municipality can receive feedback and sugges- tions for improvement measures. A common, standardized data platform also ena- bles long-term follow-up and comparison, and the Municipality aims to continuing this reporting. Järfälla is also looking into the possibility of using additional tools for monitoring climate-related measures that have been decided, to enable concrete emission and economic calculations. The Municipality’s carbon budget has also been digitized and updated to further make it more visible and easier to follow up.
Reporting and Follow-up. The climate targets in LundaEko are followed up in an annual environmental report / sustainability report submitted to the Municipal Council. The Municipality of Xxxx follows up and reports back on the work of the Covenant of Mayors 2030 to CDP's and ICLEI’s global reporting platform for cities Both 2020 and 2021, the municipality received the highest rating (A-listed) for its reporting, which confirms that Xxxx is an international leader in its climate work.
Reporting and Follow-up. In the event that a compliance issue is identified during any Compliance Review, Orthofix shall investigate the incident consistent with established Policies and Procedures for the handling of investigations. As part of the formal investigation procedures, findings shall be made and all necessary and appropriate responsive action (including disciplinary action) and corrective action shall be taken. The Chief Compliance Officer shall disclose Reportable Events pursuant to Section III.I above, if applicable. The Compliance Office shall maintain records of any compliance issues identified during a Compliance Review and any corrective action. Orthofix shall include a summary of the IMP and its results as part of each Annual Report. Orthofix shall make the reports for all IMP activities available to the OIG upon request.
